PHARMACISTS’ KNOWLEDGE AND ATTITUDES ABOUT ADRS REPORTING AND PHARMACOVIGILANCE PRACTICE IN EGYPTIAN HOSPITALS”

Marwa Kamal¹*, Mohamed Mahmoud Abdel-Latif² and Sahar Badr Hassan²

¹Department of Clinical Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt 
²Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt

**Background:** Pharmacovigilance is the practice of discovering and reducing risks associated with pharmaceutical products, as well as improving patient safety by evaluating the risk-benefit ratio of medications. The current study looked at pharmacists' knowledge, attitudes, and practices regarding ADR reporting, as well as the factors that may influence reporting.

**Methods:** A cross-sectional questionnaire-based survey was conducted to collect data from 258 pharmacists from May 2020 to September 2021. A pre-designed questionnaires evaluating knowledge, attitude and practice were distributed and filled questionnaires were collected and analyzed.

**Results:** More than third of pharmacists were unsure to whom ADRs reports should be reported, and about 26.36% said ADRs should be reported to the national ADR monitoring center. More than third group of pharmacists (34.11%) said that pharmacists are responsible for reporting ADRs, while (65.89%) said that all healthcare providers should report ADRs.

**Conclusions:** Most pharmacists had sufficient knowledge of pharmacovigilance and maintained a positive attitude towards ADRs reporting. Education and training of ADRs reporting can be used as one of the planning strategies to improve the reporting rate. This trial is registered with ClinicalTrial.gov, number NCT05224804.

**Keywords:** pharmacists, knowledge, adverse drug reactions, reporting, pharmacovigilance.

**INTRODUCTION**

The gathering, identification, monitoring, assessment, and prevention of adverse drug effects using drug products is referred to as pharmacovigilance.¹ The terms “pharmacovigilance” are derived from the Greek words pharmakon (drug) and vigilare (vigilance) (monitor or keep an eye on).² Pharmacovigilance (PV) is described as "the science and techniques associated to the identification, assessment, understanding, and prevention of adverse effects or other drug-related problems" by the World Health Organization (WHO).³ PV evaluates a medicine's risk-benefit profile in order to improve patient safety. As a result, ADR reporting is the foundation of any PV system, and early detection and reporting of ADRs to regional or national drug-regulatory agencies is critical.⁴

The World Health Organization defines an adverse drug reaction (ADR) as "an unpleasant and unexpected reaction to a treatment that occurs at doses typically used in man for the prevention, diagnosis, or therapy of disease, or for the adjustment of physiological function."⁵ Adverse drug reactions (ADRs) are a major public health concern connected to prolonged hospital stays and greater therapy expenditures. The rate of hospital admissions due to ADRs is between 3-5 percent, according to current systematic reviews and meta-analyses of observational literature.⁶

Healthcare professionals, particularly pharmacists, have been related to reporting ADRs for a variety of reasons. Several studies have identified reasons why observed ADRs are not reported, and pharmacists have been
poll to identify the most important facilitators and barriers to spontaneous reporting. Inman coined the term "seven deadly sins," which Lopez-Gonzalez et al. described as "professional and personal attributes, as well as knowledge and attitudes toward reporting." A variety of impediments to reporting ADRs have been identified by pharmacists around the world, including lack of time, the inability to link an adverse event (AE) to a specific medicine, and the lack of readily available reporting forms.

Egypt joined the WHO International Program for Drug Monitoring in 2001, but until 2009, when the Egyptian Pharmacovigilance Center (EPVC) was founded, no actual activities were taken. EPVC's tasks include receiving ADR reports, detecting safety signals, issuing frequent newsletters with PV-related updates, and performing awareness training.

In Egypt, spontaneous reporting is a voluntary process in which pharmacists and other health-care professionals can send an ADR report (yellow card) to EPVC's regional satellite centres. These centres act as focal points for disseminating information about the Egyptian ADRs reporting process by arranging workshops for healthcare professionals, including hospital pharmacists. Given Egypt's limited experience with PV, little is known about Egyptian pharmacist attitudes toward ADRs monitoring and the difficulties that pharmacists confront.

Traditionally, pharmacist's responsibilities were limited to the preparation and administration of drugs prescribed by a doctor. The function of the pharmacist has recently expanded to cover other aspects of patient care. These responsibilities include reporting ADRs, improving patient health, and improving financial results. However, in many countries, pharmacists' knowledge of pharmacovigilance and ADR reporting is insufficient, and the incidence of reporting is low.

Community pharmacists’ knowledge, behaviors, and experiences with regard to spontaneous reporting of ADRs must be evaluated. Pharmacists can assist other healthcare providers in learning more about the ADR reporting method if they have a thorough understanding of it. As a result, the current study aimed to learn about the pharmacists' demographics, as well as their knowledge of ADR reporting, attitudes about reporting, and the factors that they considered might influence reporting.

**METHODS**

**Study design**

A cross-sectional questionnaire-based survey was conducted on pharmacists from May 2020 to September 2021 in different practice settings. A pre-designed questionnaire which was structured to obtain the demographics of the pharmacists, information about their knowledge of ADR reporting, attitudes to reporting and the perceived factors that may influence reporting. The questionnaire wording was checked by experts with specialization in pharmacovigilance, clinical pharmacy and regulatory affairs.

**Ethical approval**

The study protocol was approved by the faculty of pharmacy research committee at Fayoum University. Furthermore, written consent was also requested from the respondents. Questions that may disclose the personal identity of the pharmacists or pharmacies were concealed. This trial is registered with ClinicalTrial.gov, (ID number NCT05224804).

**Data collection**

The investigators went to the pharmacists' offices to invite them to take part in an anonymous survey that was administered by hand. The crew provided no more support or explanation in addressing the questions. On a separate front sheet, the survey provided consent to participate in the study. The respondents, as well as the volume of business when the survey was presented to them, determined how long it took them to complete the survey. The interviewing crew was advised by the participating pharmacists to ensure that all survey questions were answered completely.

**Study questionnaire**

A validated Knowledge, Attitude and Practices (KAP) questionnaire was used as a tool for data collection. This questionnaire consisted of three sections. The first one included pharmacist’s demographic data, the second section assessed pharmacists’ knowledge about pharmacovigilance. The final part included questions to assess pharmacists’ attitude towards ADRs reporting. The
questionnaire consisted of a total of 36 questions; 8 questions about demographic details of the participant pharmacists, 10 questions were used to measure knowledge and awareness of adverse drug reactions reporting among pharmacists and 18 questions were used to measure attitudes of pharmacists towards ADRs reporting.

**Questionnaire distribution and data presentation**

A total of 300 pharmacists were approached and questionnaire forms were distributed to pharmacists in different practice settings. Questionnaire was handed to them after explaining them the aim of the study. The pharmacists were asked to complete the questionnaire and hand it back after completion. Descriptive statistics including frequency and percentage was used to present the data.

**Statistical Analysis**

The SPSS V.25 program was used to statistically evaluate the results. Descriptive statistics include data descriptions such as mean (± SD) for quantitative data and frequency and proportion for qualitative data.

**RESULTS AND DISCUSSION**

**Results**

**Sociodemographic characteristics of the respondents**

A total of 258 pharmacists participated in the current study. The sociodemographic characteristics of the respondents are shown in Table (1). More than half of the participants (74.80%) were between the ages of 20 and 30. The majority of the participants (86.05%) were females, and more than half of the pharmacists (61.62%) had less than five years of experience. Almost majority of the pharmacists had a bachelor's degree, with only two (0.78%) having a master's degree and seven (2.71%) having other qualifications (diploma in pharmacy). Only almost half of the participants (47.67%) work in public hospitals, with the rest working in private hospitals (19%), medical centres (12.79%), and other settings (20.54%).

| Characteristics | Number (%) |
|-----------------|------------|
| Age (years)     |            |
| 20-30           | 193 (74.80) |
| 31-40           | 60 (23.26)  |
| 41-50           | 5 (1.94)    |
| >50             | -           |
| Gender          |            |
| Male            | 36 (13.95)  |
| Female          | 222 (86.05) |
| Years of experience |        |
| <5              | 159 (61.62) |
| 5-9             | 45 (17.44)  |
| 10-20           | 49 (19)     |
| >20             | 5 (1.94)    |
| Qualification degree |      |
| B.Sc            | 249 (96.51) |
| M.Sc            | 2 (0.78)    |
| Ph.D            | -           |
| Others          | 7 (2.71)    |
| Type of hospital/pharmacy |      |
| Public          | 123(47.67)  |
| Private         | 49(19)      |
| Medical center  | 33(12.79)   |
| Clinic          | -           |
| Others          | 53(20.54)   |
| Residence       |            |
| City            | 217(84.11)  |
| Village         | 40(15.50)   |
| Rural           | 1(0.39)     |
| Employment status |         |
| Full time       | 173(67.05)  |
| Part time       | 67(25.97)   |
| Not working     | 18(6.98)    |

**Knowledge and awareness of ADRs reporting among pharmacists**

Regarding knowledge and awareness of adverse drug reaction reporting among pharmacists, responses to the ADR reporting are presented in Table 2. The majority of pharmacists who took part in the study (98.44%) agreed that not all medications on the market are safe, and the majority of them (87.21%) reported seeing a suspected ADR. About third of the participants (29.84%) were aware of the legislation governing ADRs reporting, and about half of the participants (44.57%) were aware that their institution had an ADRs reporting mechanism. Only 37.21% of pharmacists were aware of critical information for reporting ADRs. A third of the participants (34.50%) had previously attended
an ADRs workshop or awareness programme, while 70.93% had heard of pharmacovigilance. The existence of a national pharmacovigilance centre in Egypt was known by more than half of the pharmacists (62.79%). Only 42.64% of the pharmacists who took part in the study grasped the precise definition of pharmacovigilance. The most essential aim of pharmacovigilance, according to pharmacists, is to uncover previously undetected ADRs (32.56%), to determine the drug's safety (27.91%), to determine the occurrence of ADRs (23.26%), and to determine predisposing variables to ADRs (23.26%).

Attitudes of pharmacists towards ADRs reporting

Regarding attitudes of pharmacists towards ADRs reporting, only 13.57% of them reported a possible ADR. When asked if their institution's ADR reporting system encourages them to report more, approximately 23.26% of pharmacists said yes. Almost half of the pharmacists (50.78%) said there was a record of ADRs reported and that they were receiving sufficient feedback on their reported ADRs. The majority of pharmacists who took part in the survey (91.09%) said they counsel patients about adverse drug reactions, and they all believe that an ADR reporting system will benefit patients or improve the patient care process. ADR reporting is a requirement for 81.01 percent of pharmacists, and the majority (95.74%) believe pharmacovigilance should be taught in depth to medical undergraduate students, (Table 3).

Table 2: Knowledge and awareness of adverse drug reactions reporting among pharmacists.

| Questions                                                                 | Response          | n (%)       |
|---------------------------------------------------------------------------|-------------------|-------------|
| Are you aware that not all drugs available in the market are safe?        | Yes               | 254(98.44)  |
|                                                                           | No                | 2(0.78)     |
|                                                                           | Do not know       | 2(0.78)     |
| Have you ever observed a suspected ADR?                                  | Yes               | 225(87.21)  |
|                                                                           | No                | 33(12.79)   |
| Are you aware of laws governing ADRs reporting?                           | Yes               | 77(29.84)   |
|                                                                           | No                | 181(70.16)  |
| Are you aware of existence of ADRs reporting system at your institution? | Yes               | 115(44.57)  |
|                                                                           | No                | 143(55.43)  |
| Are you aware of essential information for reporting ADRs?                | Yes               | 96(37.21)   |
|                                                                           | No                | 162(62.79)  |
| Have you previously attended any ADRs workshop or awareness programs?     | Yes               | 89(34.50)   |
|                                                                           | No                | 169(65.50)  |
| Have you previously heard of Pharmacovigilance?                          | Yes               | 183(70.93)  |
|                                                                           | No                | 75(29.07)   |
| Are you aware of existence of national pharmacovigilance center in Egypt?| Yes               | 162(62.79)  |
|                                                                           | No                | 96(37.21)   |

Definition of Pharmacovigilance is:
- The science detecting the type and incidence of ADRs after drug is marketed.
- The science of monitoring ADRs occurring in a hospital.
- The process of improving the safety of the drug.
- The detection, assessment, understanding and prevention of adverse effects of drugs

The most important purpose of pharmacovigilance is:
- To identify safety of the drug
- To identify incidence of ADRs
- To identify predisposing factors to ADRs
- To identify previously unrecognized ADRs

| Definition of Pharmacovigilance is:                                        | n (%)       |
|---------------------------------------------------------------------------|-------------|
|                                                                           | 113(43.80)  |
|                                                                           | 24(9.30)    |
|                                                                           | 11(4.26)    |
|                                                                           | 110(42.64)  |
| The most important purpose of pharmacovigilance is:                        | 72(27.91)   |
|                                                                           | 60(23.26)   |
|                                                                           | 42(16.27)   |
|                                                                           | 84(32.56)   |
Table 3: Attitudes of pharmacists towards ADRs reporting.

| Questions                                                                 | Response          | n (%)         |
|---------------------------------------------------------------------------|-------------------|---------------|
| Have you ever reported a suspected ADR?                                   | Yes               | 35(13.57)     |
|                                                                           | No                | 223(86.43)    |
| If so, does the ADR reporting system exist at your institution encourage you to report further? | Yes   | 60(23.26)     |
|                                                                           | No                | 198(76.74)    |
| Is there a record of ADRs reported?                                       | Yes               | 131(50.78)    |
|                                                                           | No                | 127(49.22)    |
| Are you getting proper feedback to your reported reaction?                | Yes               | 114(44.19)    |
|                                                                           | No                | 144(55.81)    |
| Do you counsel patients about adverse drug reactions?                     | Yes               | 235(91.09)    |
|                                                                           | No                | 23(8.91)      |
| Do you think that ADR reporting system would benefit the patient or improve the patient care? | Yes   | 256(99.22)    |
|                                                                           | No                | 2(0.78)       |
| Do you think ADRs reporting is an obligation to you?                     | Yes               | 209(81.01)    |
|                                                                           | No                | 9(3.49)       |
|                                                                           | Do not know       | 40(15.5)      |
| Do you think pharmacovigilance should be taught in detail to medical undergraduate students? | Yes   | 247(95.74)    |
|                                                                           | No                | 0             |
|                                                                           | Do not know       | 11(4.26)      |

Frequency of ADRs reporting

More than half of pharmacists (51.94 percent) experienced ADRs only infrequently, (41.86%) encountered an ADR occasionally, and (6.20%) encountered an ADR frequently. Only 35.66% of pharmacists didn't know who to report ADRs to, and about 26.36% of pharmacists said ADRs should be reported to the national ADR monitoring centre, Figure 1.

Sources of information about ADRs and types of ADRs reporting

Figure 2 shows that around 48.45% of participants acquired information regarding ADRs from the internet, followed by textbooks (34.88%) and coworkers (20.16%). A large majority of participants (62.40%) agreed that all types of ADRs should be reported, Figure 3.
Factors of ADRs reporting

The presence of an awareness environment at their institution (61.24%) and the simplicity of the reporting system’s operation (40.70%) are two characteristics that pharmacists believed can motivate them to report a suspected ADR, as shown in Figure 4. The presence of administrative barriers (29.46%), a feeling that there is no benefit for reporting (27.13%), incomplete patient details (23.64%), non-availability of the ADR reporting form (21.32%), and a lack of encouragement from hospital administration were the main factors discouraging pharmacists from reporting suspected ADRs (18.99%), Figure 5.
Regarding the responsibility for reporting ADRs, about 65.89% of pharmacists said that all healthcare workers should report ADRs, and more than a third (34.11%) said that pharmacists are in charge of reporting. Educating healthcare professionals (67.44%), establishing national awareness programmes on ADRs reporting (29.46%), and producing a monthly bulletin on ADRs were among the suggestions made by pharmacists to improve ADRs reporting (24.42%).
Establishing ADR monitoring center

Regarding opinion about establishing ADR monitoring center, according to the majority of pharmacists (82.17%), it should be in every hospital. One should be in each city, according to 16.67% of respondents. While 1.16% believe it is not required in all hospitals. The majority of pharmacists (84.50%) had no idea where the international centre for ADRs monitoring was located.

Discussion

In the current study, more than half of the participants (68.6%) were young people between the ages of 20 and 30 year. The bulk of the participants (87.86%) were females, and over half of the pharmacists (53.57%) had less than five years of experience. Almost majority of the pharmacists had a bachelor's degree, with only 1.43% having a master's degree. The majority of the participants work in public hospitals (48.57%), while others work in private hospitals (27.86%). These results agreed with Alraie et al., 15 found the majority of the pharmacists in the survey were female and between the ages of 25 and 29 (86.1%). Furthermore, 84.3% attended a state Egyptian university, compared to 15.7% who attended a private Egyptian university. 70.5% earned a bachelor's degree as their highest educational achievement. Furthermore, 33.9% worked in MOH hospitals and had at least seven years of experience. In addition, Mahmoud et al., 16 revealed that the average age of the participants was 29.9 years. 79.4% were Egyptian graduates who had completed their bachelorette degree (98.1%). The bulk of the participants (66.7%) worked in chain community pharmacies.

The present study showed that, 97.14% agreed that not all medications on the market are safe, and 87.14% reported seeing a suspected ADR. 32.86% were aware of the legislation governing ADRs reporting, and 49.29% were aware that their institution had an ADRs reporting mechanism. 43.57% knew what information was needed to report ADRs. The presence of a national pharmacovigilance centre in Egypt was known by 60.71% of pharmacists. Compared with our results, Kassa and Biru, 17 found 87.7% reported knew that all medications on the market are unsafe. In addition, 20.2% of respondents were familiar with the word pharmacovigilance and recognized what it meant. Similarly, 21.1% and 22.8% respondents were aware of the national reporting system and the ADR reporting form, respectively. Which are comparable with the finding of Angamo et al., 18 who studied in the Jimma zone (19.5%). Also, Alraie et al., 15 showed low reporting rates of ADRs. This variation can be explained by Hedeiro et al., 19 that, pharmacists’ knowledge of PV practices greatly influences their reporting of ADRs.

In the current study, 29.29% had previously attended an ADRs workshop or awareness programme, while 73.57% had only heard of pharmacovigilance. Only half of the pharmacists who took part in the study knew what pharmacovigilance meant. Adisa and Omitogun20 found 72.5% of health workers heard about pharmacovigilance, with 36.2% informed about it through other healthcare professionals. While they had a smaller number of people who understood the full concepts of pharmacovigilance. These confirmed by Gavaza et al.,21; Granas et al.,22, which found instructional programmes that clarify pharmacists’ roles and enhance their understanding of ADR reporting may have an impact on their reporting rates and actions. Only small percentage of pharmacists returned yellow cards to EPVC in the six months after the workshop, indicating that training measures alone may not be adequate to foster a "reporting culture" among hospital pharmacists. The understanding of ADRs to be reported was favorably influenced by the awareness session attended, according to Figueiras et al.,23, who found out that the expected change in physician's reporting after an intervention program increased five folds, with cluster correlation coefficient of 0.005.

In the present study, pharmacists mentioned that most significant purposes of pharmacovigilance were to find previously unrecognised ADRs (40.71%), to determine medication safety (26.43%), to determine ADR incidence (19.29%), and to determine predisposing variables to ADRs (13.57%). This is in line with the most prevalent goals of an ADR spontaneous reporting system, according to Vessal et al.,24 were to uncover previously unknown ADRS (61%), measure the incidence of ADR (60%), and compare ADRS of the same pharmaceutical from different drug businesses (38%). Furthermore, to compare ADRS for drugs in similar therapeutic classes (37%), as well as to discover variables that may predispose to ADR (32%). In the other side, Zawiah et al.25 found 98.1% of pharmacists
stated that the major objective of ADRs reporting is to enable the safe drug to be identified.

Regarding attitudes of pharmacists towards ADRs reporting by the participated pharmacists, only 12.14 percent of them said they encountered an ADR. 22.14% of pharmacists thought that their institution’s ADR reporting system encourages them to report more. 47.14% said there was a record of ADRs reported and that they were receiving proper feedback on their ADRs. 90% of respondents said they advise patients about adverse drug reactions, and 100% believed that ADR reporting system would benefit patients or improve the patients’ care process. ADR reporting is a responsibility for pharmacists, according to 79.29%, and pharmacovigilance should be taught in details to medical undergraduate students, according to 94.29%.

Nearly results were reported by Kassa and Biru, 17 reported 87.7% agreed that ADR reporting should be part of their job, 76.3% agreed that ADR reporting should be mandatory, and 73.7% felt that one ADR report makes a difference. Furthermore, 108.7% and 88.6% felt that reporting ADR is important for the public and enhances patient care quality, respectively. ADRs should be reported spontaneously on a frequent basis, according to 77.2% health professionals, with 76.3% underlining that there should be assurance for ADRs connected to the drug before reporting.

Besides, 58.77% of respondents were aware that all HCPs are responsible and an obligation to report ADRs to the concerned body. While, our findings were lower than that reported by Wilbur et al.,26 as one-third of respondents had submitted a suspected ADR report in Qatar and 21% in Turkey. But our rate was higher than reported in community pharmacist populations documented recently in the region, approximately 10% in Saudi Arabia. Greater familiarity with pharmacovigilance; regular interaction with patients having serious ADRs; and tight communications with physicians who may delegate reporting of ADRs have all been cited as factors for such inpatient site-related variations in reporting.

This study reported that, 63.57% encountered ADR rarely, 30.71% encountered an ADR occasionally and 5.71% encountered an ADR commonly. Only 34 (29.82%) of respondents had at least one patient with ADR in the previous 12 months of clinical practice, according to Kassa and Biru 17, with 70.59% and 50% recording and reporting ADRs, respectively. Furthermore, Suyagh et al.,27 revealed that 91.2% of pharmacists had seen at least one adverse drug reaction in a patient per year, but only 19.5% had ever reported one.

This study found less than half of the participated pharmacists (41.43%) did not know to whom reporting should be addressed and about 27.14% of the pharmacists indicated that ADRs should be reported to national ADR monitoring center. While, in the study of Mahmoud et al.,16 most pharmacists claimed that they had submitted ADRs to the Ministry of Health and SFDA. Also, in the study by Bawazir,28, the majority of pharmacists surveyed claimed that they had submitted ADRs to both the pharmaceutical company and the Ministry of Health. These varied results may be related to little awareness to reporting. Additionally, Kassa and Biru,17 reported 37 (32.5%) and 32 (28.1%) of the respondents responded that ADRs should be reported to EFDA and Drug and therapeutic Committee (DTC) of the respective health facility, respectively.

The present study demonstrated that, approximately 65% of the participants get information about ADRs from the internet followed by textbooks (34.29%) and colleagues (20.71%). Other findings were reported by Kassa and Biru,17 discovered that more than half of the respondents (64 (56.1%)) used the National Drug Formulary and Standard Treatment Guideline (STG) as their primary sources of information about ADR, followed by standard text books (53 (46.5%).

In the current study, all types of ADRs should be disclosed, according to 71.43% of respondents. While (16%, 11%, 10%, 5%, and 1%, respectively) showed that any adverse events, novel drug reactions, unexpected reactions, seriousness of events, and only proven ADR reactions to the drug should be reported. Only major and life-threatening ADRs should be reported, according to a large percentage of respondents (81.58%), while 21.05% were aware that mild to moderate unexpected, certain, and suspected reactions must be recorded, according to Kassa and Biru 17. In addition, in the study by Cheema et al.,29, To both children and adults, all pharmacists emphasized that they would report both large and minor ADRs from drugs marked with a
black triangle. In addition, POM would produce substantial reactions in more than 90% of patients. Furthermore, Fadare et al.,20 discovered that the vast majority of respondents (>70%) were aware that suspected, significant, and specific reactions should be recorded. The disparity across studies could be explained by community pharmacists' propensity to report an adverse event, which is more likely to influence the ADR reporting method.

The presence of an awareness atmosphere at their institution (61.43%), followed by the simplicity of the reporting system's operation, were among the elements that pharmacists in this study can motivate them to report a suspected ADR (40%). As with the finding of the Zawiah et al., study25, who asked pharmacists what motivates them to report ADRs. The vast majority of respondents stated that they were only encouraged to submit ADRs when the reaction was classed as serious (95.6%). Suyagh et al.,27 also discovered that the nature and severity of ADRs are two factors that caused pharmacists to report them. Pharmacists preferred to keep track of serious reactions, as well as rare and previously undocumented reactions.

In our study, factors discouraging pharmacists to report suspected ADRs were, feeling that no benefit for reporting (29.28%), presence of administrative barriers (26.43%), non-availability of the ADR reporting form (23.57%) and lack of encouragement from hospital administration (23.57%). In this vein, Alraie et al.,15 reported that the most common reasons given by respondents for not reporting ADRs in Egypt were that the reporting method was unknown, clinicians were uninformed of the process, resulting in a communication problem, difficulty filling out patient information, and inability to link AE to medication prescribed. In the follow-up phone call, the most common cited deterrents to reporting ADRs were a lack of time, administrative barriers, and the inability to complete patient details. Our results were lower than those reported by Kassa and Biru,17 lack of feedback (58.8%), reporting forms not available when needed (46.4%), not known where to report (46.4%), and not known how to fill out and report the report form (41.2%) were among the reasons given by respondents for not reporting ADRs. In addition, Adisa and Omitogun20 found that unavailability of the reporting form (37.4%), insufficient clinical knowledge (32.7%), lack of experience in filling out the ADR reporting form (9.4%), non-threatening nature of ADRs (9.4%), complicated nature of ADR reporting (6.5%), fear of liability (3.7%), and lack of time to report ADRs were all barriers to health workers reporting ADRs (0.9%).

In addition, Vessal et al.,24 found the most common reasons for not reporting were "uncertain association," "too insignificant to mention," "too well known to report," and "yellow card not available." These differences may be due to the fact that our study had a smaller sample size than others. Toklu et al.,31 agreed, stating that Turkish pharmacists did not regard ADR reporting as a natural job for their profession, explaining that the prescriber bears primary responsibility. This helps participants understand that all members of the health-care team can contribute to medication safety and effectiveness.32 Also, Alraie et al.,13 reported that doctors and nurses play an essential role in ADR reporting. According to Zawiah et al.,25, 88.3% of pharmacists believe that pharmacists are responsible for reporting ADRs, followed by doctors (86.4%) and drug firms (62.1%). In contrary, Carandang et al.,33 found 86% nurses and 72% of physicians had a good knowledge about ADR reporting and 61% of pharmacists had an adequate knowledge.

In this study, pharmacists suggested that education of the healthcare professionals (63.57%), issued a monthly bulletin on ADRs (37.14%) holding national awareness programs on ADRs reporting (29.29%) are ways to improve ADRs reporting. Cheema et al.,25 have underlined the importance of providing community pharmacists with explicit education and training in order to improve their understanding and awareness of ADRs. Smith and Webley's34 previous study on the extent of pharmacovigilance education delivered to pharmacy students found a higher level of interest in the issue.

Limitations of the study

Some pharmacists stated that their pharmacy did not have internet access, which could have led to the underreporting of ADRs. In addition, the severe workload of community pharmacists may have hampered response rates. In addition, several hospital pharmacists also have a part-time job in a community pharmacy. Nonetheless, our findings revealed information regarding Egyptians' understanding and
perceptions of PV activities, which can be used as a starting point for future research.

Conclusions
The majority of pharmacists were educated on pharmacovigilance and viewed ADR reporting favorably. The notion that there is no benefit to reporting suspected ADRs, the presence of administrative impediments, the lack of availability of the ADR reporting form, and the lack of encouragement from hospital administration are all factors that deter pharmacists from reporting suspected ADRs. To increase pharmacists' comprehension and awareness of the ADR reporting procedure, pharmacovigilance authorities should take the necessary efforts to implement interventional programmes as soon as practicable. Education and training in ADR reporting are one of the planning approaches for increasing the reporting rate.

Acknowledgments
The authors thank the clinical pharmacist Zeinab Barakat for help in data distribution and collection.

Conflicts of Interest
The authors declare no conflict of interest.

Funding
No sources of funding were used to assist in the preparation of this article.

REFERENCES
1. MD. Kengar, KK. Patole, AK. Ade, SM . Kumbhar, CD. Patil and AR. Ganjave, "Introduction to Pharmacovigilance and Monitoring", Asian J Pharm Res, 9(2), 116-122 (2019).
2. D. Alshayban, MA. Mahmoud, MA. Islam, S. Alshammari, D. Alsuilaiman, "Pharmacovigilance Perception and Knowledge Among Pharmacists and Interns in Saudi Arabia", Risk Manag Healthc Policy, 13, 55-61 (2020).
3. M. Hans and SK. Gupta, "Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices", Perspect Clin Res, 9(4), 170-174(2018).
4. P. Bandiera, M. Gianetta, S. Leone, A.Lupi, D. Petruzzeelli and S. Bianco, "Patient Associations as key players in pharmacovigilance: results of an Italian survey from the Patient Safety Council", Pharmadvances, 3(3), 567-575 (2021).
5. N. Kumar, B. Narendra, K. Upendra and K.Rajesh, "A review on Adverse drug reactions monitoring and reporting", Int J Pharm Res Technol, 9(2),12-15(2019).
6. A. Bénard-Laribièere, G. Miremont-Salamé, MC. Pérolt-Pochat, P. Noize, F. Haramburu, centres ESGobotFnop, " Incidence of hospital admissions due to adverse drug reactions in F rance: the EMIR study", Fundam Clin Pharmacol, 29(1), 106-111 (2015).
7. TM. AlShammari and MJ. Almoslem, "Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multi-centre cross sectional study", Saudi Pharm J, 26(7), 925-931 (2018).
8. E. Lopez-Gonzalez, MT.Herdeiro, A. Figueiras, " Determinants of under-reporting of adverse drug reactions", Drug Saf, 32(1), 19-31(2009).
9. M. Reumerman, J. Tichelaar, B. Piersma, M. Richir and M. Van Agtmael, " Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature", Eur J Clin Pharmacol, 74(10), 1235-1248(2018).
10. FS. ELkhwsy, I. El Sayed, OGM. Yassine, S. Abdelmonem and MM. Salama, "Healthcare professionals’ knowledge and practice of and attitudes towards pharmacovigilance in Alexandria, Egypt: a cross-sectional survey", Drugs Ther Perspect, 37(3), 124-136(2021).
11. K. Danekhu, S. Shrestha, S. Aryal and PR. Shankar, "Health-care professionals’ knowledge and perception of adverse drug reaction reporting and Pharmacovigilance in a tertiary care teaching Hospital of Nepal", Hosp Pharm, 56(3), 178-186 (2021).
12. D. Kopciuch, T. Zaprutko, A. Paczkowska, P.Ratajezak, Ł. Zieleńska-Tomczak, K. Kus and E.Nowakowska, "Safety of medicines—Pharmacists’
knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process", *Pharmacoepidemiol Drug Saf*, 28(12), 1543-1551(2019).

13. S. Kim, YM. Yu, M. You, KH. Jeong and E. Lee, "A cross-sectional survey of knowledge, attitude, and willingness to engage in spontaneous reporting of adverse drug reactions by Korean consumers", *BMC Public Health*, 20(1), 1-11(2020).

14. V. Paudyal, A. Al-Hamid, M. Bowen, MA. Hadi, SS. Hasan, Z. Jalal and D. Stewart, "Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: Systematic review and meta-analysis", *Expert Opin Drug Saf*, 19(9), 1173-1191(2020).

15. NA. Alraie, AA. Saad, NA. Sabry and SF. Farid, "Adverse drug reactions reporting: a questionnaire-based study on Egyptian pharmacists’ attitudes following an awareness workshop", *J Eval Clin Pract*, 22(3), 349-355(2016).

16. MA. Mahmoud, Y. Alswaida, T. Alshammarri, TM. Khan, A. Alrasheedy, MA. Hassali and H. Aljadhey, "Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia", *Saudi Pharm J*, 22(5), 411-418 (2014).

17. B. Kassa Alemu and TT. Biru, "Health care professionals’ knowledge, attitude, and practice towards adverse drug reaction reporting and associated factors at selected public hospitals in Northeast Ethiopia: a cross-sectional study", *Biomed Res Int*, 2019, 8690546(2019).

18. MT. Angamo, A. Tesfa and NT. Wabe, "Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Health Professionals in Southwest Ethiopia", *TAF Prev Med Bull*, 11(4), 397-406 (2012).

19. MT. Herdeiro, A. Figueiras, J. Polónia and J. Gestal-Otero, "Influence of pharmacists’ attitudes on adverse drug reaction reporting", *Drug Saf*, 29(4), 331-340(2006).

20. R. Adisa, TI. Omitogun, "Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria", *BMC Health Serv Res*, 19(1), 926(2019).

21. P. Gavaza, CM. Brown, KA. Lawson, KL. Rascati, JP. Wilson, M. Steinhardt, "Influence of attitudes on pharmacists’ intention to report serious adverse drug events to the Food and Drug Administration", *Br J Clin Pharmacol*, 72(1), 143-152(2011).

22. AG. Granas, M. Buajordet, H. Stenberg-Nilsen, P. Harg and AM. Horn, "Pharmacists’ attitudes towards the reporting of suspected adverse drug reactions in Norway", *Pharmacoepidemiol Drug Saf*, 16(4), 429-434 (2007).

23. A. Figueiras, MT. Herdeiro, J. Pol’nia and JJ. Gestal-Otero, "An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial", *JAMA*, 296(9), 1086-1093(2006).

24. G. Vessal, Z. Mardani and M. Mollai, "Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran", *Pharm World Sci*, 31(2), 183-187(2009).

25. M. Zawiah, R. Mukred, S. Al-Jamei, T. Kadi, A. Al-Baidani, R. Abu Farha, "Pharmacists' knowledge and perceptions about pharmacovigilance and barriers towards adverse drug reactions reporting in Yemen", *J Pharm Health Serv Res*, 10(1), 67-72(2019).

26. K. Wilbur, "Pharmacovigilance in Qatar: a survey of pharmacists", *East Mediterr Health J*, 19(11), 930-935 (2013).

27. M. Suyagh, D. Farah and RA. Farha, "Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process", *Saudi Pharm J*, 23(2), 147-153(2015).

28. A. Saleh, "Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction", (2006).

29. E. Cheema, A. Haseeb, TM. Khan, P. Sutcliffe and DR. Singer, "Barriers to
reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom”, *Pharm Pract (Granada)*, 15(3), 931(2017).

30. JO.Fadare, OO. Enwere, A. Afolabi, B.Chedi and A.Musa, "Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria”, *Trop J Pharm Res*, 10(3), 235-242 (2011).

31. HZ. Toklu and MK. Uysal," The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul", *Pharm World Sci*, 30(5), 556-562 (2008).

32. A. Somers, M. Petrovic, H. Robays and M.Bogaert, "Reporting adverse drug reactions on a geriatric ward: a pilot project", *Eur J Clin Pharmacol*, 58(10), 707-714(2003).

33. RR.Carandang, K.Cao, NB.Jose, FD.Almonte and RM.Tinio, "Research article knowledge and attitudes on adverse drug reaction reporting of selected hospital-based health practitioners in Manila, Philippines”, *Sch Acad J Pharm*, 4, 301-307(2015).

34. MP. Smith and SD. Webley, "Pharmacovigilance teaching in UK undergraduate pharmacy programmes”*, *Pharmacoepidemiol Drug Saf*, 22(3), 223-228 (2013).
Marrfa al-siyada wa-mawqifhum horol tahari al-tafalat al-dowaniyyah al-ustersa

waamarasa licyat al-dowaniyya fi al-mustansifiyat al-misriyya

Mroua Kamal 1*, Mohamed Mahmoud Abd al-latif 2, Sahr Badr Hossen

1 Qasim al-siyada al-akliniyya, klia al-siyada, jawma al-fibum, al-fibum, misr
2 Qasim al-siyada al-akliniyya, klia al-siyada, jawma al-fibum, assiut, misr

The pharmacy department is a discovery of a comprehensive and reduced risk of drugs. Conducted by the current study was in the precaution of the consequences of the actions and their consequences, what is related to the consequences of the drug side effects, and the addition to the consequences of the study. It is a 2011 report. Then the report was repeated and issued from the field (2017) of the first approval and renewal of the drug side effects. Can be seen from the results that the drug which caused ADR (178, 423%) is the drug side effects and 75.5% of the reports were on the drug side effects. It was shown also that the drug side effects were not responsible for all the drug side effects. It was concluded that the drug side effects are a serious and urgent matter. In order to improve the rate of drug side effects, the study recommended a set of strategies to improve and track the drug side effects.